EMEA-000920-PIP01-10

Human medicines European public assessment report (EPAR): Palbociclib Viatris, palbociclib, Date of authorisation: 19/06/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Agamree, vamorolone, Date of authorisation: 14/12/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Imdylltra, tarlatamab, Date of authorisation: 29/05/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Adstiladrin, nadofaragene firadenovec, Date of authorisation: 28/05/2026, Status: Authorised

Annex 22 expert workshop draft agenda: Day 1 - session with interested parties

EMA/PE/0000233122

Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0352/2022

EMA/PE/0000241855

Opinion/decision on a Paediatric investigation plan (PIP): Kavigale, sipavibart, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Surgical and medical procedures, PIP number: P/0504/2023